Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…
SILVER SPRING, Md., Sept. 12, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC)…
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract…
Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised…
Vironexis’s off-the-shelf, single-dose gene therapies aim to deliver cancer treatments that are safer, more effective and long-lasting, and more easily…
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well…
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused…
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination…